The stock of Naturally Splendid Enterprises Ltd (CVE:NSP) hit a new 52-week high and has $0.68 target or 38.00% above today’s $0.49 share price. The 9 months bullish chart indicates low risk for the $30.66M company. The 1-year high was reported on Nov, 8 by Barchart.com. If the $0.68 price target is reached, the company will be worth $11.65 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock last traded at $0.49 per share. It is down 6.00% since October 9, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
More notable recent Naturally Splendid Enterprises Ltd (CVE:NSP) news were published by: Marketwired.com which released: “Naturally Splendid Enterprises Ltd. Featured in CANNAINVESTOR Magazine” on August 16, 2016, also Globenewswire.com with their article: “Naturally Splendid Receives $3.2 Million to Complete Private Placement” published on November 08, 2016, Marketwired.com published: “Naturally Splendid Secures Additional $2100000 Purchase Order for Export” on July 21, 2016. More interesting news about Naturally Splendid Enterprises Ltd (CVE:NSP) were released by: Marketwired.com and their article: “Naturally Splendid USA Secures Agreement to License Hemp and Cannabinoid …” published on November 20, 2014 as well as Globenewswire.com‘s news article titled: “Naturally Splendid Announces Increase To Private Placement Financing” with publication date: October 14, 2016.
Naturally Splendid Enterprises Ltd. is a biotechnology company, which is engaged in the business of developing, commercializing, producing, selling and licensing hemp-derived Omega foods, nutritional food enhancers and related products. The company has a market cap of $30.66 million. The Company, through BPC Manufacturing Corp., operates a facility that processes a range of products, including a suite of plant omega technologies, such as HempOmega. It currently has negative earnings. It has an agreement with Medropharm GmbH, which specializes in the production, extraction, research and formulation of raw materials and products derived from industrial hemp.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.